Caribou Biosciences to End Drug Development, Cut Staff Due to Funding Problems

By Katherine HamiltonCaribou Biosciences is exploring strategic alternatives and cutting jobs after it decided to discontinue the development of two of its cancer products.The biopharmaceutical company said Tuesday it would cease development of vispa-cel, which was designed to treat lymphoma, and C…